<DOC>
	<DOCNO>NCT01318421</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety tolerability ELND002 patient multiple sclerosis ( MS ) participation study MS103 .</brief_summary>
	<brief_title>A Study ELND002 Patients With Relapsing Forms Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>This study open subject complete week 12 visit study ELND002MS103 take assign dose study drug . Subject new medical contraindication continue participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Relapsing form secondary progressive multiple sclerosis ( SPMS ) relapsing-remitting multiple sclerosis ( RRMS )</keyword>
</DOC>